Stay updated on BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial
Sign up to get notified when there's something new on the BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial page.

Latest updates to the BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial page
- Check4 days agoChange DetectedThe study record for the spesolimab palmoplantar pustulosis trial is displayed, including its design, outcome measures, eligibility criteria, and study locations.SummaryDifference91%

- Check11 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check25 days agoChange DetectedA general notice about changes to NIH website terminology appears above the ClinicalTrials.gov error page, and the site revision label is updated.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the previous content with a minimal error screen and a Home link. This indicates the page is currently inaccessible due to access restrictions or a server issue.SummaryDifference18%

- Check60 days agoChange DetectedThe page shows a new revision tag (v3.7.0) replacing the previous v3.6.6, signaling an updated version of the page content.SummaryDifference0.0%

Stay in the know with updates to BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial page.